Investor Presentaiton

Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity Investor Presentation - 2016 Product Portfolio • 6 existing products; > 50 filings across 14 major countries. 5 new products in clinical development 5 new products in early development FY20 Business Emerging Markets Revenue: $150Mn - $200Mn • Profile • Developed Markets Profits/Royalties expected to Kick-in EBITDA margin post R&D: > 25 % FY25 • Emerging Markets Revenue: $300Mn - $400Mn Business • Developed Markets Profits: ~ $150 - 200Mn Profile • EBITDA margin post R&D: > 35 % Dr. Reddy's Laboratories Ltd. 26

View entire presentation